

IN THE SPECIFICATION:

Pursuant to 37 C.F.R. §§ 1.121 and 1.125 (as amended to date) please enter the substitute specification in clean form and including paragraph numbers [0001] through [0196], references, tables and Abstract attached hereto as Appendix A. A marked-up substitute specification to clearly identify amendments to the specification as required by 37 C.F.R. § 1.121(b)(3)(iii) is attached hereto as Appendix B. It is respectfully submitted that the substitute specification does not introduce new matter into the above-referenced patent application.

Please add the attached sequence listing to the above referenced application after the claims.

IN THE CLAIMS:

Please cancel claims 2, 4, 8, 9, 18-21, 23-34, 37-41, 43, 45, 47, 49, 51-54, 57, 58, 63, 64, and 69-72 without prejudice or disclaimer.

B1
5. (Twice amended) The method according to claim 1, wherein at least one of the proteinaceous substance harvested is encoded by said gene.

B2
7. (Twice amended) The method according to claim 1, wherein said at least one adenoviral E1 protein comprises an E1A protein or a functional homologue, fragment and/or derivative thereof.

B3
11. (Twice amended) The method according to claim 1, wherein said proteinaceous substance is a protein that undergoes post-translational and/or peri-translational modification.

B4
13. (Twice amended) The method according to claim 1, wherein said proteinaceous substance is erythropoietin.